Retrospective study on drug interaction of tuberculosis and pulmonary Mycobacterium avium complex disease therapeutic drugs by using data of clinical symptoms and laboratory test results.

Retrospective study on drug interaction of tuberculosis and pulmonary Mycobacterium avium complex disease therapeutic drugs by using data of clinical symptoms and laboratory test results. - Retrospective study on drug interaction of tuberculosis and pulmonary Mycobacterium avium complex disease therapeutic drugs by using data of clinical symptoms and laboratory test results.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010588

Enrollment

Registered

2013-04-24

Start date

2013-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis and pulmonary Mycobacterium avium complex disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Study on interaction with rifampicin and diabetes therapeutic drugs in tuberculosis patients: tuberculosis patients with diabetes who administered rifampicin from 2008 to 2012. 2) Study on interaction with rifampicin and clarithromycin in pulmonary Mycobacterium avium complex disease patients: pulmonary Mycobacterium avium complex disease patients who received drug therapy from 2008 to 2012. 3) Study on interaction with clarithromycin and levofloxacin in pulmonary Mycobacterium avium complex disease patients: pulmonary Mycobacterium avium complex disease patients who received drug therapy from 2010 to 2012.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
1) Study on interaction with rifampicin and diabetes therapeutic drugs in tuberculosis patients: blood glucose and hemoglobin A1c level. 2) Study on interaction with rifampicin and clarithromycin in pulmonary Mycobacterium avium complex disease patients: clinical symptoms of subjects (cough, sputum and hemosputum etc. ), chest radiographic findings, examination of sputum (smear and culture) and clinical laboratory test results. 3) Study on interaction with clarithromycin and levofloxacin in pulmonary Mycobacterium avium complex disease patients: clinical outcome of subjects (smear and culture test).	—

Measure

Time frame

1) Study on interaction with rifampicin and diabetes therapeutic drugs in tuberculosis patients: blood glucose and hemoglobin A1c level. 2) Study on interaction with rifampicin and clarithromycin in pulmonary Mycobacterium avium complex disease patients: clinical symptoms of subjects (cough, sputum and hemosputum etc. ), chest radiographic findings, examination of sputum (smear and culture) and clinical laboratory test results. 3) Study on interaction with clarithromycin and levofloxacin in pulmonary Mycobacterium avium complex disease patients: clinical outcome of subjects (smear and culture test).

—

Countries

Japan

Contacts

Public ContactTakao Aoyama

Tokyo University of Science Faculty of Pharmaceutical Sciences

t-aoyama@rs.noda.tus.ac.jp04-7124-1501

Outcome results